Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MBRX

Moleculin Biotech Inc

Mar 31 • 04:00PM ET

0.9736

Dollar change -0.0664
Percentage change -6.38	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX FATE AFMD KPTI AVIR ADAP IMMP XFOR BYSI HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.12	Insider Own	0.83%	Shs Outstand	14.00M	Perf Week	-8.15%
Market Cap	13.63M	Forward P/E	-	EPS next Y	-1.64	Insider Trans	0.00%	Shs Float	13.88M	Perf Month	-24.53%
Income	-21.76M	PEG	-	EPS next Q	-0.56	Inst Own	3.32%	Short Float	3.34%	Perf Quarter	-44.99%
Sales	0.00M	P/S	-	EPS this Y	73.47%	Inst Trans	2.28%	Short Ratio	0.08	Perf Half Y	-60.10%
Book/sh	1.77	P/B	0.55	EPS next Y	2.49%	ROA	-78.93%	Short Interest	0.46M	Perf Year	-82.43%
Cash/sh	0.31	P/C	3.18	EPS next 5Y	37.81%	ROE	-135.80%	52W Range	0.40 - 6.09	Perf YTD	-42.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.36%	ROI	-343.43%	52W High	-84.01%	Beta	2.16
Dividend TTM	-	Quick Ratio	0.97	Sales past 5Y	0.00%	Gross Margin	-	52W Low	144.93%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	0.97	EPS Y/Y TTM	52.82%	Oper. Margin	-	RSI (14)	40.64	Volatility	11.34% 12.09%
Employees	17	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.67
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	89.13%	Payout	-	Rel Volume	0.06	Prev Close	1.04
Sales Surprise	-	EPS Surprise	119.48%	Sales Q/Q	-	Earnings	Mar 24 BMO	Avg Volume	5.69M	Price	0.97
SMA20	-12.03%	SMA50	-22.73%	SMA200	-58.22%	Trades		Volume	351,765	Change	-6.38%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform	$14

Mar-26-25 12:00PM	All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy (Zacks) -6.96%
Mar-25-25 03:00AM	Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com) +8.49%
01:38AM	Q4 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-24-25 10:50AM	Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:05AM	Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:05AM	Loading…
Mar-19-25 08:05AM	Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast (GlobeNewswire)
Mar-11-25 08:45AM	Moleculin Biotech, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (PR Newswire)
Mar-10-25 08:45AM	Moleculin to Present at the 37th Annual ROTH Conference (PR Newswire)
Mar-06-25 08:30AM	Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity (PR Newswire) -5.17%
Mar-03-25 08:30AM	Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium (PR Newswire) -10.85%
Feb-25-25 12:35PM	Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) +20.56%
Feb-13-25 01:19PM	Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? (Benzinga) +202.38%
01:05PM	Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds (PR Newswire)
09:25AM	Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Feb-12-25 10:25AM	Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine (Clinical Trials Arena) -17.24%
08:40AM	Loading…
Feb-11-25 08:40AM	Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial (PR Newswire) -27.91%
Jan-27-25 08:30AM	Moleculin Participates in Virtual Investor 'What This Means' Segment (PR Newswire)
Jan-08-25 08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 and 2026 (PR Newswire)
08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 (PR Newswire)
Dec-11-24 08:00AM	Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model (PR Newswire) +14.72%
Nov-18-24 08:15AM	New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML (PR Newswire) -7.01%
Nov-14-24 08:15AM	Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 (PR Newswire) +23.11%
Nov-12-24 10:59PM	Moleculin Biotech Reports Financial Highlights and Future Plans (TipRanks) +5.18%
08:00AM	Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Nov-11-24 11:19PM	Q3 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 09:00AM	Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast (PR Newswire)
Nov-04-24 08:30AM	Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Oct-18-24 08:57AM	Moleculin Biotech Highlights Annamycins AML Treatment Potential (TipRanks) +9.53%
Oct-17-24 08:40AM	Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available (PR Newswire)
05:02PM	Loading…
Oct-09-24 05:02PM	Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... (GuruFocus.com)
Oct-07-24 08:30AM	Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 (PR Newswire) +6.36%
Oct-04-24 09:00AM	Moleculin to Present at Two Upcoming Investor Conferences (PR Newswire)
Sep-23-24 08:00AM	Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma (PR Newswire) +14.35%
Sep-16-24 08:30AM	Moleculin Participates in Virtual Investor 'What this Means' Segment (PR Newswire)
Sep-09-24 08:15AM	Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma (PR Newswire)
Sep-03-24 09:15AM	Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 08:30AM	Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (PR Newswire) +6.69%
Aug-19-24 04:05PM	Moleculin Announces Closing of up to $16.5 Million Public Offering (PR Newswire) +7.08%
Aug-16-24 08:00AM	Moleculin Announces Pricing of up to $16.5 Million Public Offering (PR Newswire) +9.42%
Aug-14-24 08:05AM	Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +6.38%
Aug-05-24 09:05AM	Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET (PR Newswire) -6.95%
Aug-01-24 08:30AM	Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial (PR Newswire) -27.94%
Jul-10-24 08:30AM	Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML (PR Newswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:00AM	Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial (PR Newswire)
Jun-12-24 09:00AM	Moleculin to Present at the Virtual Investor Pitch Conference (PR Newswire)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-05-24 08:55AM	Moleculin to Participate in the Virtual Investor Lunch Break Series (PR Newswire) +7.95%
May-16-24 08:32AM	Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress (PR Newswire)
06:22AM	Moleculin begins NIH-funded Phase II glioblastoma treatment trial (Clinical Trials Arena)
May-15-24 08:38AM	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) (PR Newswire)
May-14-24 03:00AM	Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
May-13-24 07:30AM	Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-10-24 09:52PM	MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:30AM	Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin (PR Newswire)
May-08-24 08:45AM	Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast (PR Newswire) -7.66%
May-07-24 08:55AM	Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data (PR Newswire)
May-02-24 09:00AM	Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 (PR Newswire)
May-01-24 08:50AM	Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Apr-25-24 09:45AM	Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
Apr-18-24 08:30AM	European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) (PR Newswire) +5.69%
Apr-10-24 08:30AM	Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties (PR Newswire)
Mar-28-24 10:45AM	Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference (PR Newswire) +6.68%
Mar-27-24 09:25AM	Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity (PR Newswire) +18.38%
09:05AM	Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML (PR Newswire)
Mar-26-24 08:36AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.86%
Mar-25-24 07:30AM	Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial (PR Newswire) -7.97%
Mar-22-24 08:52PM	MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023 (InvestorPlace) -13.96%
05:31PM	Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
04:05PM	Moleculin Reports Full Year 2023 Financial Results (PR Newswire)
Mar-20-24 07:30AM	Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast (PR Newswire) -19.70%
Mar-19-24 04:30PM	Moleculin Announces Reverse Stock Split (PR Newswire)
Mar-12-24 09:05AM	Moleculin to Present at the 36th Annual ROTH Conference (PR Newswire) -11.22%
Jan-24-24 08:50AM	Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 (PR Newswire) +11.08%
Dec-20-23 09:16PM	Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (PR Newswire)
Dec-11-23 08:50AM	Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting (PR Newswire) -8.07%
Nov-14-23 01:46PM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:29AM	Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies (Zacks)
Nov-13-23 08:05AM	Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months (PR Newswire) +6.70%
08:00AM	Moleculin Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 08:45AM	Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast (PR Newswire) -5.53%
Nov-06-23 08:35AM	Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases (PR Newswire) +14.97%
Oct-24-23 07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -5.91%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Moleculin to Participate in the Virtual Investor Ask the CEO Conference (PR Newswire) +5.58%
Oct-02-23 08:40AM	Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
Sep-22-23 07:58AM	Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up (Zacks) -7.14%
Sep-21-23 08:50AM	Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107) (PR Newswire) +9.95%
Sep-18-23 08:40AM	Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin (PR Newswire)
Sep-14-23 08:35AM	Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (PR Newswire)
Sep-05-23 08:35AM	Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-12-23 12:16AM	Q2 2023 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-11-23 06:45AM	Moleculin Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-10-23 04:05PM	Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones (PR Newswire)
Aug-07-23 08:40AM	Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling (PR Newswire)
Aug-03-23 08:45AM	Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast (PR Newswire)
Jul-13-23 08:40AM	Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) (PR Newswire) +17.72%
Jul-06-23 08:45AM	Moleculin to Participate in the Virtual Investor Summer Spotlight Series (PR Newswire)
Jun-13-23 08:35AM	Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (PR Newswire)

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your FINVIZ experience